SGO1, shugoshin 1, 151648

N. diseases: 41; N. variants: 2
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Chronic atrial and intestinal dysrhythmia
0.720 GeneticVariation disease BEFREE A new study identifies homozygous missense mutations in SGOL1, which encodes a component of the cohesin complex, in a newly described disorder termed Chronic Atrial and Intestinal Dysrhythmia (CAID) syndrome. 25352100 2014
Chronic atrial and intestinal dysrhythmia
0.720 Biomarker disease GENOMICS_ENGLAND Our findings identify CAID syndrome as a novel generalized dysrhythmia, suggesting a new role for SGOL1 and the cohesin complex in mediating the integrity of human cardiac and gut rhythm. 25282101 2014
Chronic atrial and intestinal dysrhythmia
0.720 Biomarker disease BEFREE Morpholino-induced knockdown of sgol1 in zebrafish recapitulated the abnormalities seen in humans with CAID syndrome. 25282101 2014
Chronic atrial and intestinal dysrhythmia
0.720 GermlineCausalMutation disease ORPHANET Our findings identify CAID syndrome as a novel generalized dysrhythmia, suggesting a new role for SGOL1 and the cohesin complex in mediating the integrity of human cardiac and gut rhythm. 25282101 2014
Chronic atrial and intestinal dysrhythmia
0.720 GeneticVariation disease UNIPROT Our findings identify CAID syndrome as a novel generalized dysrhythmia, suggesting a new role for SGOL1 and the cohesin complex in mediating the integrity of human cardiac and gut rhythm. 25282101 2014
Chronic atrial and intestinal dysrhythmia
0.720 Biomarker disease CTD_human
Chronic atrial and intestinal dysrhythmia
0.720 CausalMutation disease CLINVAR
CUI: C0003811
Disease: Cardiac Arrhythmia
Cardiac Arrhythmia
0.300 Biomarker phenotype CTD_human Our findings identify CAID syndrome as a novel generalized dysrhythmia, suggesting a new role for SGOL1 and the cohesin complex in mediating the integrity of human cardiac and gut rhythm. 25282101 2014
CUI: C0021831
Disease: Intestinal Diseases
Intestinal Diseases
0.300 Biomarker group CTD_human Mutations in SGOL1 cause a novel cohesinopathy affecting heart and gut rhythm. 25282101 2014
CUI: C0236811
Disease: Chronobiology Disorders
Chronobiology Disorders
0.300 Biomarker group CTD_human Mutations in SGOL1 cause a novel cohesinopathy affecting heart and gut rhythm. 25282101 2014
CUI: C0813142
Disease: Circadian Rhythm Disorders
Circadian Rhythm Disorders
0.300 Biomarker disease CTD_human Mutations in SGOL1 cause a novel cohesinopathy affecting heart and gut rhythm. 25282101 2014
Psychogenic Inversion of Circadian Rhythm
0.300 Biomarker disease CTD_human Mutations in SGOL1 cause a novel cohesinopathy affecting heart and gut rhythm. 25282101 2014
CUI: C0015544
Disease: Failure to Thrive
Failure to Thrive
0.100 Biomarker disease HPO
CUI: C0037052
Disease: Sick Sinus Syndrome
Sick Sinus Syndrome
0.100 Biomarker disease HPO
CUI: C0428977
Disease: Bradycardia
Bradycardia
0.100 Biomarker phenotype HPO
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.040 Biomarker phenotype BEFREE Antagonizing pathways leading to differential dynamics in colon carcinogenesis in Shugoshin1 (Sgo1)-haploinsufficient chromosome instability model. 25773652 2016
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.040 Biomarker phenotype BEFREE Tumor-promoting/progressing role of additional chromosome instability in hepatic carcinogenesis in Sgo1 (Shugoshin 1) haploinsufficient mice. 25740822 2015
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.040 Biomarker phenotype BEFREE Shugoshin1 (SGO1) is an important player in appropriate chromosome segregation and is involved in tumorigenesis. 23564482 2013
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.040 Biomarker phenotype BEFREE Recent studies have identified shugoshin (SGO-1) as an important player in proper chromosome segregation and the involvement in tumorigenesis. 22161216 2012
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.030 Biomarker disease BEFREE Further, loss of SGOL1 from HCC cell decreased the cytotoxicity of sorafenib in vivo. 29467456 2018
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.030 Biomarker group BEFREE We propose that formation of ACF in Sgo1(-/+) mice is facilitated by the IL6-STAT3-SOCS3 oncogenic pathway and by the Bcl2-anti-apoptotic pathway, yet further development of the ACF to tumors is inhibited by the p16(INK4A) tumor suppressor pathway. 25773652 2016
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.030 Biomarker disease BEFREE Treatment with the carcinogen azoxymethane caused Sgo1(-/+) ME-CIN model mice to develop HCCs within 6 months, whereas control mice developed no HCC (P < 0.003). 25740822 2015
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.030 Biomarker disease BEFREE Together, these results highlight the essential role of Sgo1 in the maintenance of a proper mitotic progression in hepatoma cells and suggest that Sgo1 is a promising oncotarget for HCC. 25638162 2015
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.030 GeneticVariation disease BEFREE The aim of this study was to explore whether SGOL1 and PDS5B genes are mutated and expressionally altered in gastric and colorectal cancers. 23850494 2013
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.030 Biomarker group BEFREE Both SGOL1 and PDS5B are considered putative tumor suppressor genes. 23850494 2013